<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02170974</url>
  </required_header>
  <id_info>
    <org_study_id>1160.52</org_study_id>
    <nct_id>NCT02170974</nct_id>
  </id_info>
  <brief_title>Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.</brief_title>
  <official_title>Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Polymorph II Capsule Relative to 150 mg HPMC Polymorph I Capsule in Healthy Subjects. A Two-way Crossover, Randomised, Open Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigation of the relative bioavailability of BIBR 953 ZW after administration of 150 mg
      BIBR 1048 polymorph II versus BIBR 953 ZW after administration of 150 mg BIBR 1048 polymorph
      I in HPMC capsules
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-infinity (area under the plasma concentration-time curve of BIBR 953 ZW from 0 to infinity)</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured plasma concentration of BIBR 953 ZW)</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to when the plasma concentration reaches Cmax after extravascular doses )</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (half life)</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo (mean time of residence of drug molecules in the body)</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F (apparent clearance after oral administration)</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F (apparent volume of distribution)</measure>
    <time_frame>0 h (predose), 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, and 72 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ECG</measure>
    <time_frame>up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic and diastolic blood pressure</measure>
    <time_frame>up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 31 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a four-point scale</measure>
    <time_frame>up to 31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BIBR 1048 MS polymorph II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BIBR 1048 MS polymorph I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS polymorph II</intervention_name>
    <arm_group_label>BIBR 1048 MS polymorph II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBR 1048 MS polymorph I</intervention_name>
    <arm_group_label>BIBR 1048 MS polymorph I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female and male subjects as determined by results of screening

          -  Signed written informed consent in accordance with GCP and local legislation

          -  Age ≥ 18 and ≤ 55 years

          -  BMI ≥ 18.5 and ≤ 29.9 kg/m2

        Exclusion Criteria:

          -  Any finding at the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders

          -  History of relevant orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  History of

               -  allergy/hypersensitivity (including drug allergy) which is deemed relevant to the
                  trial as judged by the investigator

               -  any bleeding disorder including prolonged or habitual bleeding

               -  other hematologic disease

               -  cerebral bleeding (e.g. after a car accident)

               -  commotio cerebri

          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs that might influence the results of the trial within 10 days prior to
             administration or during the trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Drug abuse

          -  Blood donation of more than 400 ml within 4 weeks prior to administration or during
             the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Any laboratory value outside the reference range of clinical relevance

          -  History of any familial bleeding disorder

          -  Platelets &lt; 150000/μl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

